Resources

Comprehensive recommendations feature notable new recommendations for people with cardiovascular disease and diabetes.

Identifying causes of death and related risk factors in patients with type 2 diabetes and cardiovascular disease may help with prevention.

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.

Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.

New SGLT-2 inhibitor can be used as add-on therapy to provide better improvement in HbA1C in patients with type 2 diabetes.

Obesity, independent of diabetes diagnosis, found to increase diabetes risk.

Do you use texting or email to converse with your patients? Follow the link to see how you compare to your colleagues.

One of your patients has referred her 21-year-old stepson for a new patient exam. He has recently arrived home from college for the summer and she is concerned because he always seems to be thirsty. When prompted, she recalls her husband saying his ex-wife struggled with her weight and took “pills for her blood sugar.” Physical examination is notable for mildly elevated BP (137/84) and BMI 26 kg/m2. He denies any cigarette or alcohol use, states his favorite activities revolve around video games, and that he doesn’t really enjoy any physical activities. Labs are notable for random plasma glucose 312 mg/dl, UA positive for glucose. What would your initial drug therapy strategy be? A. Initiate monotherapy with metformin B. Initiate a combination therapy with two noninsulin agents C. Initiate lifestyle modifications D. Initiate insulin therapy Follow the link for the answer.

Aaron Kowalski, PhD is the Chief Mission Officer and Vice President of Research at JDRF. He was appointed the JDRF's first Chief Mission officer in December 2014 and serves as a key link between JDRF and the broad diabetes community.

Transcript: Dr. Aaron Kowalski on the meaning of his role as Chief Mission Officer of JDRF, and the work being funded to advance the cause of curing type 1 diabetes one day, as well as toward improving the quality of life for diabetes patients today.